SOURCE: NanoAntibiotics

March 27, 2014 10:00 ET

NanoAntibiotics Provides Update on Its Novel Efflux Pump Inhibitor

SURFSIDE, FL--(Marketwired - Mar 27, 2014) - NanoAntibiotics (OTCBB: NNAB) (the "Company"), a development stage nano-biotechnology company focused on the discovery, development, and commercialization of new anti-infective drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens, is pleased to report successful preliminary in vitro results on its novel efflux pump inhibitor.

The current study involved testing for efflux pump inhibition in Staphylococcus epidermis, a common gram-positive bacterium. In the study, the bacteria were incubated with a tracer dye to observe real time monitoring of its membrane transport systems. The results showed that the bacteria treated with our efflux pump inhibitor demonstrated retention of the tracer dye (showing they were not able to expel the dye), whereas no dye retention was observed in the untreated bacteria. Further studies are ongoing.

The company is excited about these results and its continuing progress to identify and optimize key nano efflux pump inhibitors to "target" and "block" some of the most deadly gram-positive and gram-negative bacteria.

Bacteria Efflux Pumps:

Bacteria efflux pumps are intrinsic defense mechanisms that expel antibiotics before they reach their target and kill the bacteria. These pumps reside in bacterial cell walls and are a leading cause of multi-drug resistance. There are currently no anti-microbial drugs in use to inhibit the activity of these efflux pumps. There is a need for an effective pump inhibitor which would restore the potency of once effective antibiotics which have been rendered insensitive.

About NanoAntibiotics, Inc.

NanoAntibiotics is a developmental stage nano-biotechnology company focused on the development and commercialization of novel therapeutics for multi-drug resistant gram-positive and gram-negative bacteria (also known as Superbugs).

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause NanoAntibiotics' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. NanoAntiobiotics has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are NanoAntibiotics' need for, and the availability of, substantial capital in the future to fund its operations and research and development. The fact that NanoAntibiotics' compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in NanoAntibiotics' filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. NanoAntibiotics undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Contact Information

  • Contact:
    INVESTOR AND MEDIA CONTACT:
    NanoAntibiotics, Inc.
    Elliot Ehrlich
    Email Contact